Abcam, ab251304, Anti-FXYD1/PLM antibody [EPR16082] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal FXYD1/PLM antibody. Carrier free. Suitable for IP, WB and reacts with Human, Mouse, Rat samples.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR16082,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Mouse, Rat, Human,
Applications:WB, IPSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab251304 is the carrier-free version of
ab200204
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-Do Not Freeze

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
FXYD1 also known as phospholemman (PLM) is a small transmembrane protein with a molecular mass of approximately 15 kDa. It is expressed mainly in cardiac and skeletal muscles where it plays a mechanical role in regulating ion transport across cell membranes. This protein modulates the activity of the Na+/K+-ATPase pump influencing the transport of sodium and potassium ions which is important for maintaining cellular homeostasis.
Biological function summary
Phospholemman participates in the regulation of cardiac contractility and is involved in muscle relaxation processes. As a component of the Na+/K+-ATPase pump complex it affects the pump's affinity for sodium ions which is important for its normal function. The effector actions of FXYD1 are modulated by phosphorylation allowing it to serve as an important regulator of cardiac output under varying physiological conditions.
Pathways
Phospholemman features in the ion homeostasis and excitability pathway where its action on the Na+/K+-ATPase pump links it to regulation of cardiac action potential. This regulation involves interaction with other membrane proteins like ankyrin which further connects FXYD1 to integrative cardiovascular mechanisms. Additionally FXYD1 impacts membrane hyperpolarization positioning it in the pathway that controls cell excitability and signal transduction in muscle tissues.
Dysregulation of FXYD1 is linked to heart failure and arrhythmias. Altered expression or function of this protein can affect Na+/K+-ATPase efficiency leading to imbalanced ion transport and compromised cardiac function. Interaction with proteins such as cAMP-dependent protein kinase also implicates FXYD1 in various cardiac pathologies influencing the therapeutic targeting of this protein in cardiovascular diseases.